369 related articles for article (PubMed ID: 24086418)
1. Genomic insights into triple-negative and HER2-positive breast cancers using isogenic model systems.
Mudvari P; Ohshiro K; Nair V; Horvath A; Kumar R
PLoS One; 2013; 8(9):e74993. PubMed ID: 24086418
[TBL] [Abstract][Full Text] [Related]
2. Reverse engineering of triple-negative breast cancer cells for targeted treatment.
Bluemel L; von Wahlde MK; Tio J; Kiesel L; Bernemann C
Maturitas; 2018 Feb; 108():24-30. PubMed ID: 29290211
[TBL] [Abstract][Full Text] [Related]
3. FGF13 promotes metastasis of triple-negative breast cancer.
Johnstone CN; Pattison AD; Harrison PF; Powell DR; Lock P; Ernst M; Anderson RL; Beilharz TH
Int J Cancer; 2020 Jul; 147(1):230-243. PubMed ID: 31957002
[TBL] [Abstract][Full Text] [Related]
4. Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.
Liu Y; Li M; Fang Z; Gao S; Cheng W; Duan Y; Wang X; Feng J; Yu T; Zhang J; Wang T; Hu A; Zhang H; Rong Z; Shakila SS; Shang Y; Kong F; Liu J; Li Y; Ma F
Cancer Immunol Immunother; 2024 May; 73(7):117. PubMed ID: 38713229
[TBL] [Abstract][Full Text] [Related]
5. Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells.
Adinew GM; Messeha SS; Taka E; Badisa RB; Antonie LM; Soliman KFA
Nutrients; 2022 May; 14(10):. PubMed ID: 35631261
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive
Henry KE; Dilling TR; Abdel-Atti D; Edwards KJ; Evans MJ; Lewis JS
J Nucl Med; 2018 Jan; 59(1):51-57. PubMed ID: 28848040
[TBL] [Abstract][Full Text] [Related]
7. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
[TBL] [Abstract][Full Text] [Related]
8. Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis.
Zhong G; Lou W; Shen Q; Yu K; Zheng Y
Mol Med Rep; 2020 Feb; 21(2):557-566. PubMed ID: 31974598
[TBL] [Abstract][Full Text] [Related]
9. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM
Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
Tseng LM; Chiu JH; Liu CY; Tsai YF; Wang YL; Yang CW; Shyr YM
Breast Cancer Res Treat; 2017 Jun; 163(2):241-254. PubMed ID: 28299476
[TBL] [Abstract][Full Text] [Related]
11. Endocan as a prognostic biomarker of triple-negative breast cancer.
Sagara A; Igarashi K; Otsuka M; Kodama A; Yamashita M; Sugiura R; Karasawa T; Arakawa K; Narita M; Kuzumaki N; Narita M; Kato Y
Breast Cancer Res Treat; 2017 Jan; 161(2):269-278. PubMed ID: 27888420
[TBL] [Abstract][Full Text] [Related]
12. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
13. 3-D chromatin conformation, accessibility, and gene expression profiling of triple-negative breast cancer.
Llinàs-Arias P; Ensenyat-Méndez M; Orozco JIJ; Íñiguez-Muñoz S; Valdez B; Wang C; Mezger A; Choi E; Tran YZ; Yao L; Bonath F; Olsen RA; Ormestad M; Esteller M; Lupien M; Marzese DM
BMC Genom Data; 2023 Nov; 24(1):61. PubMed ID: 37919672
[TBL] [Abstract][Full Text] [Related]
14. Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab.
Li J; Ma M; Yang X; Zhang M; Luo J; Zhou H; Huang N; Xiao F; Lai B; Lv W; Zhang N
Mol Cancer; 2020 Sep; 19(1):142. PubMed ID: 32917240
[TBL] [Abstract][Full Text] [Related]
15. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
16. Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis.
He J; Yang J; Chen W; Wu H; Yuan Z; Wang K; Li G; Sun J; Yu L
PLoS One; 2015; 10(6):e0129842. PubMed ID: 26103053
[TBL] [Abstract][Full Text] [Related]
17. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
18. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
Zhai Q; Li H; Sun L; Yuan Y; Wang X
Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer.
Lai YW; Hsu WJ; Lee WY; Chen CH; Tsai YH; Dai JZ; Yang CC; Lin CW
Cells; 2021 Jul; 10(8):. PubMed ID: 34440660
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
